Prostate Cancer and Prostatic Diseases

Article	Citations
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction	77
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging	74
Comment on: The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer	66
Best of 2022 in prostate cancer and prostatic diseases	66
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?	61
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?	58
Germline alterations among Hispanic men with prostate cancer	53
Sexual outcomes in men who have sex with men who underwent radical prostatectomy	49
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)	46
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study	46
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer	44
New BPH therapy classification: what really FITs?	42
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions	40
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches	33
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study	31
More evidence that physical activity is beneficial for prostate cancer	30
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis	30
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations	29
Concerns regarding prostate cancer screening guidelines in minority populations	29
Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States	29
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro	29
Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer	29
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer	28
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study	28
TRexit is going one step further	28

Correction: Application of next-generation imaging in biochemically recurrent prostate cancer	27
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis	26
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts	26
Rezūm water vapor therapy in multimorbid patients with urinary retention and catheter dependency	25
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms	25
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy	25
Feasibility and safety study of the Flostent™ system (RAPID-I)	25
Incidence of prostate cancer in transgender women in the US: a large database analysis	24
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer	24
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions	24
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure	24
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database	24
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids	24
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	23
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer	23
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate	23
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?	23
Significant changes in macrophage and CD8 T cell densities in primary prostate tumors 2 weeks after SBRT	23
The effects of glycemic index on prostate cancer progression in a xenograft mouse model	22
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision	22
Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?	22
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients	22
The times have changed. Let the urologists change!	22
Antimicrobial prophylaxis: To do or not to do? This is the question	22
“Targeted microwave ablation: another way to kick the can(cer) down the road?”	22
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials	21
The evolving clinical use of prostate cancer biomarkers	21
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)	21
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants	21
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study	20
Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature	20
Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database	20
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy	19
Prognostic value of MR visibility/invisibility in men on Active Surveillance	18
Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics	18
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction	18
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells	18
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK	18
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!	18
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies	18
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate	18
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	18
Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system	17
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	17
Association of prostate cancer with human papillomavirus infections: a case-control study	17
Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia	17
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey	17
The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis	17
Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry	17
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis	17

A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer	16
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy	16
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	16
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT	16
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer	16
Sleep disturbances are underappreciated in prostate cancer survivorship	16
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis	16
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan	16
Correction: Estimating patient health in prostate cancer treatment counseling	16
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial	16
Risk calculators for the detection of prostate cancer: a systematic review	15
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	15
The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study	15
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores	15
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications	15
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification	15
Less is more: the “Safety Net Approach” balances precision and safety	15
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials	15
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?	14
Prevalence and determinants of shared decision-making for PSA testing in the United States	14
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy	14
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey	14
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape	14
Characteristics of incidental prostate cancer in the United States	13
Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer	13
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer	13
Cardiovascular risk in ADT recipients: does the type of ADT matter?	13
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis	13
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review	13
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial	12
The impact of race on survival in metastatic prostate cancer: a systematic literature review	12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz	12
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?	12
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed	12
Hyperglycemia and microRNAs in prostate cancer	12
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings	12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta	12
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review	12
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer	12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis	12
Biopsy strategies in the era of mpMRI: a comprehensive review	11
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes	11
The changing face of castrate resistant prostate cancer	11
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations	11
Best of 2023 in Prostate Cancer and Prostatic Diseases	11
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting	11
Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only	11
Quality of information and appropriateness of ChatGPT outputs for urology patients	11
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis	11
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study	11
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)	10
Prostate cancer and prostatic diseases is “Your” journal	10
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?	10
Quality of information and appropriateness of Open AI outputs for prostate cancer	10
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis	10
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry	10
NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	10
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?	10
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis	10
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration	10
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH	10
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients	10
Surveillance after Focal Therapy – a Comprehensive Review	10
Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer	9
Best of 2024 in Prostate Cancer and Prostatic diseases	9
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in i	9
Whack-a-met: serial SABR for repeated oligoprogression in metastatic CRPC	9
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study	9
Overcoming barriers to prostate cancer genetic testing: who, when, and how	9
Social determinants of health into evaluations of quality and appropriateness of AI assistant ChatGPT	9
15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer	9
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis	9
Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”	9
Transperineal magnetic resonance imaging targeted biopsy versus transrectal route in the detection of prostate cancer: a systematic review and meta-analysis	9
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer	9
New robotic platforms for prostate surgery: the future is now	9
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer	9
The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016	9
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment	9
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study	9

Characterisation of cell lines derived from prostate cancer patients with localised disease	8
Quality of information and appropriateness of ChatGPT outputs for urology patients	8
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care	8
Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis	8
Overview of seminal fluid biomarkers for the evaluation of chronic prostatitis: a scoping review	8
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer	8
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab	8
Impact of transperitoneal anterior, retzius-sparing, extraperitoneal, transvesical and perineal approaches on urinary continence recovery after robot-assisted radical prostatectomy: a systematic revie	8
Composite urinary and sexual outcomes after Rezum: an analysis of predictive factors from an Italian multi-centric study	8
Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers	8
Relative search popularity of five advanced prostate cancer medications using Google Trends	8
Have we mis-PRONOUNCEd the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial	8
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis	8
Transperineal laser ablation in the management of benign prostatic hyperplasia: an updated systematic review and pooled analysis	8
Comparative analysis of robot-assisted simple prostatectomy: the HUGO™ RAS system versus the DaVinci® Xi system	8
Re: Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP	8
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer	8
Concerns regarding the methodological limitations of the OASIS study	8
Racial variation in the advanced prostate cancer genome	8
Role of targeted biopsy, perilesional biopsy, random biopsy, and their combination in the detection of clinically significant prostate cancer by mpMRI/transrectal ultrasonography fusion biopsy in conf	8
Targeted and perilesional biopsy: triumphs and cautions	8
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases	8
Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores	8
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer	7
Systematic review of the impact of a plant-based diet on prostate cancer incidence and outcomes	7
Artificial intelligence for target prostate biopsy outcomes prediction the potential application of fuzzy logic	7
In regard to Boeri et al. ‘Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience’	7
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine	7
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy	7
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlle	7
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)	7
Prostate cancer screening in Europe: future directions and perspectives	7
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics	7
Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis	7
A Visual Standardized (ViSta) map integrating imaging (MRI), biopsy findings and Specimen Prostate Cancer location	7
Integrating clinical and technological perspectives to enhance predictive modeling in prostate cancer surgery	7
Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men	7
Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis	7
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors	7
The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates	7
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis	7
Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer—a systematic review and meta-analysis	7
Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis	7
Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer	7
Advancing the treatment of localized prostate cancer with MR-guided radiotherapy	7
Artificial intelligence applications in prostate cancer	7
Treatment cycles per unit prostate volume (CPV) for transurethral water vapor therapy (Rezūm) in catheter-dependent patients	7
Thulium fiber laser versus holmium MOSESTM laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized prospective clinical study	7
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or	6
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review	6
Head-to-head comparison of DaVinci and Hugo™ RAS robotic platforms for robot-assisted radical prostatectomy: a systematic review and meta-analysis of comparative studies	6
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board	6
Correction: Germline alterations among Hispanic men with prostate cancer	6
Prostate cancer in New York City: impact of neighborhood level social determinants of care	6
Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis	6
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer	6
Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark	6
Short term results after minimally invasive treatments for benign prostatic enlargement: the first randomized trial comparing transperineal laser ablation and water vapor ablation	6
Effect of metformin on incidence, recurrence, and mortality in prostate cancer patients: integrating evidence from real-world studies	6
Comparison of senhance and da vinci robotic radical prostatectomy: short-term outcomes, learning curve, and cost analysis	6
Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis	6
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)	6
Correction: Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning	6
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120	6
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial	6
Setting new standards: robot-assisted radical prostatectomy as a day case	6
Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia	6
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs	6
A systematic review and meta-analysis of artificial intelligence diagnostic accuracy in prostate cancer histology identification and grading	6
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide	6
Primary bladder neck obstruction in men—new perspectives in physiopathology	6
Letter to the editor: “Incidence of prostate cancer in transgender women in the US: a large database analysis.”	5
Fatty acid diet and prostate cancer: a treasure hunt or a wild goose chase?	5
Model risk scores may underestimate rate of biochemical recurrence in African American men with localized prostate cancer: a cohort analysis of over 3000 men	5
Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD	5
Guidelines for genetic testing in prostate cancer: a scoping review	5
The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort	5
Salvage treatments after focal therapy for prostate cancer – a comprehensive review	5
Instagram and prostate cancer: using validated instruments to assess the quality of information on social media	5
Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer	5
From association to action: strengthening research on social determinants of health	5
Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men	5
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis	5
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men	5
Reply to De Nunzio, Franco, and Lombardo	5
A clinical available decision support scheme for optimizing prostate biopsy based on mpMRI	5
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer	5
External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer	5
Annual Acknowledgement of Manuscript Reviewers	5
Body composition as a determinant of the therapeutic index with androgen signaling inhibition	5
ExoDx test for prostate cancer: the future is liquid—Editorial Comment	5
Perspective transition from transrectal to transperineal MRI-fusion biopsy under local anesthesia – the institutional TREXIT learning curve of the new gold standard	5
Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?	5
Correction: Natural killer cell infiltration in prostate cancers predict improved patient outcomes	5
Disparities in germline testing among racial minorities with prostate cancer	5